Organon was carved out of Merck & Co. in June 2021 with a specific mandate: focus on women’s health, a category the largest pharmaceutical companies have historically underfunded. The spinoff came with 60+ medicines, 6 manufacturing sites across 6 countries, and distribution to 140+ countries. In 2024, Organon posted $6.4 billion in revenue, with approximately 75% generated outside the United States.
On June 3, 2021, Merck & Co. completed something that pharmaceutical companies almost never do voluntarily: it took a profitable, functioning collection of medicines and separated them into an independent publicly traded company. The logic was straightforward, even if the execution was not. Merck wanted to concentrate on oncology and vaccines , Keytruda and Gardasil were generating the growth, and management attention follows revenue growth. The 60-plus established brands in women’s health, biosimilars, and mature therapeutics were profitable but not growing fast enough to compete for resources inside a company with $48 billion in revenue.
Organon inherited a portfolio that most pharmaceutical executives would consider enviable and unglamorous in equal measure. Nexplanon, the subdermal contraceptive implant, was the crown jewel , a device inserted in a physician’s office that provides three to five years of contraception. NuvaRing, the vaginal contraceptive ring, was an established franchise facing generic competition. Behind these sat dozens of established brands across cardiovascular, respiratory, dermatology, and pain management , medicines that Merck had marketed for decades but no longer prioritized.
The name itself carried history. The original Organon was founded in 1923 in Oss, the Netherlands, by Saal van Zwanenberg. That company pioneered hormone research and contraception, developing some of the first oral contraceptive pills in the 1960s. Through a series of mergers , Organon to Akzo Nobel, then to Schering-Plough, then to Merck via the 2009 acquisition , the Organon identity had been absorbed and dissolved. The 2021 spinoff resurrected the name deliberately, anchoring the new company to a legacy of reproductive health innovation that predated its corporate parent by decades.
Organon’s financial geography is unusual among American pharmaceutical companies. Approximately 75% of its $6.4 billion in 2024 revenue came from outside the United States. In 2023, international revenue was $4.8 billion out of $6.3 billion total , roughly 76%. The year before, it was approximately 77%. The ratio has been consistent since the spinoff, and it reflects a fundamental structural reality: the medicines Organon sells are disproportionately consumed in markets where the US is not the dominant revenue driver.
Contraception is the clearest example. Nexplanon, the subdermal implant, is used globally. In many lower- and middle-income countries, long-acting reversible contraceptives represent the standard of care for family planning programmes. NuvaRing, while facing generic pressure in the US, maintains market position in European and Latin American markets where the competitive dynamics differ. The established brands portfolio , cardiovascular, respiratory, dermatology , consists of molecules that have been available for decades, which means they are most widely prescribed in markets where generic competition is less immediate or where brand loyalty among physicians persists.
This international weighting creates both resilience and exposure. Currency fluctuations affect Organon more than most US-listed pharma companies. When the dollar strengthens, 75% of revenue translates into fewer dollars. But geographic diversification also insulates the company from single-market regulatory risk. A pricing decision by any one government affects a smaller share of total revenue than it would for a US-centric competitor. Between 2021 and 2024, Organon’s total revenue remained remarkably stable , $6.3 billion, $6.2 billion, $6.3 billion, $6.4 billion , even as the portfolio mix shifted and individual markets fluctuated.
When Merck assembled the portfolio that would become Organon, it included something unexpected: a biosimilars business. Hadlima (adalimumab-bwwd) is Organon’s biosimilar to AbbVie’s Humira, one of the best-selling drugs in pharmaceutical history. Renflexis (infliximab-abda) is its biosimilar to Johnson & Johnson’s Remicade, a foundational biologic for autoimmune diseases. These are not small molecules manufactured in chemical plants. They are complex biological products that require specialized manufacturing capabilities and regulatory expertise to develop and commercialize.
The biosimilars portfolio does something strategically important for Organon: it provides a growth vector that is independent of the women’s health franchise. As Humira’s market opens to biosimilar competition , a process that began in earnest in 2023 , Hadlima competes for a share of a market that once generated over $20 billion in annual revenue for a single product. Organon does not need to capture a large percentage of that market for biosimilars to meaningfully contribute to its revenue.
The combination of women’s health, biosimilars, and established brands gives Organon a three-legged structure that would be difficult to replicate through acquisition. Each segment addresses different therapeutic areas, different prescriber communities, and different competitive dynamics. Women’s health provides the mission and the identity. Biosimilars provide growth optionality. Established brands provide cash flow. The question Organon faces is whether the sum of these parts, managed independently, generates more value than they did as a neglected division of a larger company. The first four years of revenue data suggest the answer is at least stable.
Sources: Organon & Co. Annual Reports and SEC filings (10-K) 2021–2024. NYSE (OGN). OPPI member directory.